The potential for this drug is mind boggling. I was glad someone brought up NASH on the call yesterday. NASH just a few months ago was the next great indication that BP would jump in and buy rights to. It seems leadership is jumping from indication to indication with no clear focus on one or two. Although the indication with the fastest path to revenue and funding is probably best for us long time holding longs. So if this China deal pans out soonest then pursuing China deal is first priority. The thing is you have to have defined priorities and work on top priority.